Welcome to our dedicated page for Roivant Sciences Ltd. SEC filings (Ticker: ROIV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Roivant Sciences Ltd. filings document material events for a Nasdaq-listed Bermuda biopharmaceutical company with common shares registered under the ticker ROIV. The company’s recent Form 8-K disclosures cover quarterly financial results, preliminary liquidity information, share repurchases, Regulation FD updates and exhibits tied to clinical programs at subsidiaries such as Priovant Therapeutics.
Its filings also record material definitive agreements and amendments, including the Genevant Sciences settlement agreement involving lipid nanoparticle delivery technology, as well as shareholder voting results from the annual general meeting. Governance disclosures include director elections, auditor ratification and other proxy-related voting matters, while clinical exhibits describe programs such as brepocitinib in autoimmune and inflammatory diseases.
An affiliate of ROIV filed a Form 144 indicating an intention to sell 284,707 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on August 17, 2026, in connection with an Exercise of Options Under a Registered Plan, for an aggregate value of $10,320,571.81.
The filer, Mayukh Sukhatme, also reports prior open-market sales of ROIV common stock during the preceding three months: 500,000 shares for $17,051,141.93 on June 25, 2026, 500,000 shares for $17,039,650.00 on June 26, 2026, and 243,177 shares for $8,809,767.72 on August 14, 2026.
Roivant Sciences (ROIV) reporting person Mayukh Sukhatme filed a notice of proposed sale of 243,177 common shares, to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services. The shares relate to an exercise of options under a registered plan, with a proposed sale date of August 14, 2026 on NASDAQ for cash.
The filing also lists prior sales during the past three months by Mayukh Sukhatme of 500,000 common shares on June 25, 2026 for $17,051,141.93 and 500,000 common shares on June 26, 2026 for $17,039,650.00.
Morgan Stanley and Morgan Stanley Investment Management Inc. report beneficial ownership of Roivant Sciences Ltd. common shares on a Schedule 13G/A (Amendment No. 3). Morgan Stanley reports beneficial ownership of 40,693,386 common shares, representing 5.7% of the class, with 36,175,596 shares having shared voting power and 40,610,322 shares having shared dispositive power. Morgan Stanley Investment Management Inc. reports beneficial ownership of 39,432,015 shares, representing 5.5% of the class, all with shared dispositive power. The filing applies only to specified Morgan Stanley operating units defined as the MS Reporting Units and excludes disaggregated units under SEC Release No. 34-39538.
Roivant Sciences Ltd. reported a net loss of $290.6 million for the quarter ended June 30 2026, compared with $273.9 million a year earlier, on revenue of $1.4 million. Operating expenses rose to $202.0 million for research and development and $165.5 million for general and administrative costs, driven by expanded anti‑FcRn and mosliciguat programs and higher compensation, including bonuses linked to a Moderna settlement.
Roivant ended the quarter with $3.84 billion in cash, cash equivalents and marketable securities and recorded a $771.6 million litigation settlement receivable tied to Genevant’s agreement with Moderna, which was collected in July. The company repurchased 7.3 million shares for about $208.7 million and is advancing late‑stage candidates such as brepocitinib and IMVT‑1402, with several clinical readouts expected from the second half of 2026 onward.
Roivant Sciences Ltd. reported results for the three months ended June 30, 2026, with revenue of $1.4 million and a net loss of $290.6 million, compared with a $273.9 million net loss a year earlier. R&D expenses rose to $202.0 million and G&A to $165.5 million, driven in part by bonuses linked to the Moderna settlement. Non-GAAP net loss was $243.7 million, up from $170.1 million.
The company reported consolidated cash, cash equivalents, restricted cash and marketable securities of $3.9 billion as of June 30, 2026, excluding the $950 million payment Genevant and Arbutus received from Moderna in July under a $2.25 billion patent settlement, with an additional $1.3 billion contingent on a favorable Section 1498 appeal. Roivant repurchased 7.3 million common shares for approximately $208.7 million, and states this liquidity supports cash runway into profitability.
Operationally, Roivant is preparing for the potential U.S. launch of brepocitinib in dermatomyositis by the end of September 2026, has initiated a Phase 3 trial in cutaneous sarcoidosis, and continues late-stage development in non-infectious uveitis and lichen planopilaris. IMVT-1402 and mosliciguat programs remain on track, with multiple topline data readouts expected from 2026 through 2028, while Genevant pursues additional lipid nanoparticle patent actions against Pfizer and BioNTech.
Roivant Sciences Ltd. president and Immunovant CEO Eric Venker reported an option exercise and related share sale. On 2026-07-27 he exercised stock options for 200,000 Common Shares at $3.85 per share from a fully vested award, leaving 4,044,834 options of this grant outstanding, expiring April 19, 2032. He then sold 200,000 Common Shares at a weighted average price of $34.95 (with trades between $34.62 and $35.56), with the filing indicating use of a Rule 10b5-1 trading plan.
Roivant Sciences Ltd. is calling a 2026 Annual General Meeting for September 16, 2026 in London to elect two Class II directors (Daniel Gold and Meghan FitzGerald), ratify Ernst & Young LLP as auditor for the fiscal year ending March 31, 2027, and hold a non-binding advisory vote on named executive officer compensation. The Board recommends FOR all three proposals.
The company has an eight‑member, classified Board with three classes and six independent directors2 female6 male directors. Key committees (Audit, Compensation, Nominating and Governance) are fully independent, and the Chair role is separated from the CEO.
Executive pay follows a stated “pay‑for‑performance” philosophy. Fiscal 2025 annual bonuses were tied to corporate goals, which management and the Compensation Committee scored at 128% of target based on clinical, regulatory and other milestones. A multi‑year Senior Executive Compensation Program grants large performance stock unit awards to top executives, vesting only if share‑price hurdles between $15 and $30 are met over a five‑year period and service conditions are satisfied, with additional post‑vesting holding periods. The company also used sizeable one‑time cash retention bonuses, including an aggregate $2.8 million program for the CFO and a separate $7.5 million cash retention award for President and Vant Chair Frank Torti.
At the prior annual meeting, the advisory Say‑on‑Pay vote received 60.9% support, down from 89.3% a year earlier. In response, Roivant engaged with shareholders owning about half of its outstanding shares; investors were generally supportive of the long‑term incentive structure while emphasizing continued execution and adherence to the multi‑year compensation commitments.
Roivant Sciences Ltd. received a notice that affiliate Eric Venker plans to sell 200,000 common shares, expected to be issued from an option exercise granted on 04/20/2022, with a proposed sale date of 07/27/2026 on NASDAQ via wire settlement.
The notice also lists sales during the prior three months: 200,000 common shares on 05/22/2026 for an aggregate value of 6,054,730.92 and another 200,000 common shares on 06/24/2026 for an aggregate value of 6,631,659.08, each by Eric Venker.
MOMTAZEE JAMES C reported acquisition or exercise transactions in this Form 4 filing.
Roivant Sciences Ltd. director James C. Momtazee received an award of 405 Common Shares on July 17, 2026 under the Non-Employee Director Compensation Plan at $0.00 per share. The award was fully vested on grant, bringing his directly held stake to 109,810 Common Shares.